VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE™ Platform in nearly 800 enrolled patientsi IRVINE, Calif., Sept. 2, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced acute safety and effectiveness results from the VARIPURE substudy of SECURE, evaluating...Read more
Health Canada has approved ELAHERE®, the first novel therapy to demonstrate statistically significant and clinically meaningful improvements in overall survival (OS) compared to chemotherapy alone for patients with platinum-resistant ovarian cancer (PROC).1 ELAHERE® received approval through Health Canada's Priority Review process, based on data from the pivotal MIRASOL Phase 3 trial, establishing it as a potential new standard of care...Read more
NORTH CHICAGO, Ill., Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will participate in a fireside chat at 9:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be...Read more
Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials Enlicitide had a favorable safety profile, with comparable rates of discontinuation between treatment groups RAHWAY, N.J. / Sep 02, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results...Read more
Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines Zorevunersen generally well tolerated across all studies Data...Read more
SHANGHAI & JERSEY CITY, N.J. / Sep 02, 2025 / Business Wire / Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 “The FDA...Read more
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed,...Read more
MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when compared to standard care, routine use of Impella CP® in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality...Read more
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment1 Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy® users compared with tirzepatide users in...Read more
Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine WILMINGTON, Del. / Aug 30, 2025 / Business Wire / Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated...Read more
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardiology Congress 2025, zilebesiran demonstrated clinically meaningful reductions in office systolic blood pressure at month three with continuous control through month six Zilebesiran, a potential best-in-disease...Read more
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet RAHWAY, N.J. / Aug 30, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results evaluating VERQUVO® (vericiguat) in adult patients with stable chronic heart failure and reduced ejection fraction...Read more
THOUSAND OAKS, Calif., Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025. Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors...Read more
Findings from COLLIGO-HCM reinforce Camzyos’ efficacy and safety profile in reducing left ventricular outflow tract (LVOT) obstruction and improving symptom burden in a racially diverse, global patient population COLLIGO-HCM is a part of the WAYFARER-HCM global data program aimed at providing insights into use of Camzyos in real-world clinical practice PRINCETON, N.J. / Aug 29, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY)...Read more
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S. TOKYO and CAMBRIDGE, Mass., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq:...Read more
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET. Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside...Read more
TORONTO, Aug. 28, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by Régie de l'assurance maladie (RAMQ) for people in Quebec, under certain criteria, as a treatment for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard therapies.1 FRUZAQLA received...Read more
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy. Liraglutide injection is indicated for adults with obesity or overweight (excess weight) who also have weight related medical problems, and...Read more
LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in September: Citi 2025 Biopharma Back to School Summit on Wednesday, September 3 at 9:00 a.m. Eastern Time 2025 Wells Fargo Healthcare Conference on Thursday, September 4 at 9:30 a.m. Eastern Time A live webcast of Kiniksa’s...Read more
RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025, at 12:45 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast...Read more
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit Results reinforce two years of Verzenio plus endocrine therapy as the standard of...Read more
RINVOQ is the first and only oral advanced therapy approved for the treatment of giant cell arteritis (GCA) in Canadian adults1 GCA is the most common vasculitis in Canada, primarily affecting adults over 502 This marks the eighth approved indication for RINVOQ in Canada across rheumatology, gastroenterology and dermatology3 MONTREAL, Aug. 27, 2025 /CNW/ - AbbVie today announced that Health Canada has issued a Notice of...Read more
BASKING RIDGE, N.J. & RAHWAY, N.J. / Aug 27, 2025 / Business Wire / The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan (HER3-DXd) versus investigator’s choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer with disease...Read more
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the country NEW YORK & MAINZ, Germany / Aug 27, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE, “Pfizer”)...Read more
New Drug Application (NDA) for low-dose contrast agent gadoquatrane seeks approval for contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) and other body regions for adults and pediatric patients including neonates Submitted dose corresponds to a 60 percent reduction in gadolinium compared to macrocyclic gadolinium-based contrast agents (GBCAs) dosed at 0.1 mmol gadolinium per kilogram of body...Read more
Coalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis CARMEL, Ind., Aug. 27, 2025 /PRNewswire/ -- Splenda®, a leading global health and wellness brand in sweeteners, has teamed up with Elanco and HATCH, as well as other partners to sponsor Nutrition Secure Indianapolis, a first-of-its-kind program...Read more
TEANECK, N.J. / Aug 27, 2025 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5...Read more
BEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise...Read more
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 22.9 lbs (10.5%) on the highest dose, with A1C reduced by an average of 1.8% INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ --...Read more
Yeytuo® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protection Accelerated EC Decision Comes After U.S. FDA Approval in June FOSTER CITY, Calif. / Aug 26, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1...Read more
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. ET on Tuesday, September 9, 2025 (2:00 a.m. AEST, Sep 10). Dr. Christian...Read more
Psi-GAD delivers statistically significant and clinically meaningful improvements across validated measures of anxiety, mood, disability, and quality of life; results establish PSX-001 as a leading psilocybin-assisted therapy in development globally MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its...Read more
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal...Read more
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser. NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a...Read more
The $700 million project is part of Genentech and Roche’s $50 billion investment in U.S. manufacturing, infrastructure and R&D The facility will create more than 1,900 jobs and support the production of next-generation metabolic medicines, including treatments for obesity U.S. Rep. Deborah Ross, Gov. Josh Stein and other local leaders attended the groundbreaking event HOLLY SPRINGS, N.C. / Aug 25, 2025 / Business Wire /...Read more
New real-world evidence and clinical trial data provide insights into treatment patterns for several serious cardiovascular diseases, including ASCVD, PH, and HFrEF RAHWAY, N.J. / Aug 25, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain...Read more
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.' The update removes a prior requirement for a patient to have...Read more
Camzyos (mavacamten) presentations include real-world outcomes from COLLIGO-HCM and a pooled monotherapy analysis from four Phase 3 studies Results add to growing body of evidence supporting the efficacy and safety profile of this first and only approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy PRINCETON, N.J. / Aug 25, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the...Read more
3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines Substantial improvement in overall seizure burden and seizure free days observed with ongoing treatment CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB)...Read more
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. LEQEMBI...Read more
HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the...Read more
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team will present at two upcoming investor conferences as follows: EVENT: H.C. Wainwright 27th Annual Global Investment ConferenceDATE: Monday, September 8, 2025TIME: 9:00am ET EVENT: Morgan...Read more
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV, September 2-5, 2025. The posters will highlight real-world data from the company’s portfolio of pain treatments and reflect Collegium’s continued commitment to responsible pain...Read more
Evolysse™ Sculpt met the primary endpoint of non-inferiority and demonstrated statistical superiority to Restylane®-Lyft The safety profile was similar between Evolysse™ Sculpt and Restylane®-Lyft and no treatment-related serious adverse events Premarket Approval application submitted to the U.S. Food and Drug Administration; Approval expected in the second half of 2026 NEWPORT BEACH, Calif. / Aug 25, 2025 / Business Wire / Evolus,...Read more
Calgary, Canada – TheNewswire – August 25, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation") is pleased to announce the launch of its U.S.-based iodine feasibility program, a major step toward establishing a vertically integrated production system for iodine-based contrast media drugs used in diagnostic imaging. Upon completion of the feasibility study and satisfactory results, Voyageur is...Read more
The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in...Read more
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical...Read more
MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase program (the “Repurchase Program”) for up to $20 million of the Company’s outstanding shares of common stock...Read more
In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 201 Key secondary endpoints, including improvements in...Read more
SANTA MONICA, Calif. & PHILADELPHIA / Aug 21, 2025 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite's expertise in cell therapy by incorporating Interius's integrating in vivo platform. This approach...Read more
PALO ALTO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its majority-owned subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and...Read more
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Quebec and Saskatchewan. This new...Read more
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2025. Key highlights include: (CAD) Q2 2025 % Change vs.Q2 2024 H1 2025 % Change vs. H1 2024 Trailing Twelve Months (TTM)June 30, 2025 % Changevs. TTM June 30, 2024 Canadian...Read more
Calgary, Alberta, Canada – August 21, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a radiology contrast media company focused on vertical integration and supply chain security, today announces the first commercial delivery of the full suite of Voyageur’s Health Canada–approved barium contrast products. Further to the Company's news release dated June 4, 2025, the delivery was...Read more
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the...Read more
Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study) Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies) New insights into the role of inflammation in cardiovascular disease on...Read more
FOSTER CITY, Calif. / Aug 20, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM Eastern Time Wells Fargo Healthcare Conference on Thursday, September 4 at 11:00 AM Eastern Time Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 9 at...Read more
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results1 Group performance2: Reflects strategic investment for long-term value creation Revenue of $390.4 million, up by 63%3 and on track to meet full year...Read more
NEWPORT BEACH, Calif. / Aug 20, 2025 / Business Wire / Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. “This...Read more
WINNIPEG, MB / ACCESS Newswire / August 20, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2025. Quarter Ended June 30, 2025 Highlights: Recorded total net revenue of $6.7...Read more
Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo NORTH CHICAGO, Ill., Aug. 19, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of...Read more
WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia. "We are of course disappointed by the FDA's decision to not approve vatiquinone," said Matthew B. Klein, M.D., Chief...Read more
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients whose tumors harbor epidermal growth factor receptor (“EGFR”)...Read more
New agreement brings innovative shock wave, tPEMF therapy, monitoring, and bleeding control solutions to more than 2,200 member clinics nationwide ANN ARBOR, MI / ACCESS Newswire / August 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, announced today a new strategic partnership with VerticalVet,...Read more
Calgary, Alberta, Canada – TheNewswire - August 19, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a company with a strategic focus on vertically integrating the barium and iodine contrast markets, is pleased to announce that it has received significant investor support through the exercise of 14,708,013 share purchase warrants (“Warrants”) for gross proceeds of $1,470,801, which included...Read more
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the successful completion of the Single Ascending...Read more
U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification regarding the BX004 drug candidate Enrollment and dosing of patients outside the US is continuing in accordance with protocol NESS ZIONA, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...Read more
Acceptance to NVIDIA Connect Program offers access to unique tools for the development of DeepSolar’s nextgen, AI-driven, solar forecasting platform to improve weather prediction accuracy by up to 50% and optimize energy asset performance TEL AVIV, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, PainReform’s solar energy business unit developing next-generation AI-driven solar...Read more
Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung Cancer First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s ifinatamab deruxtecan based on IDeate-Lung01 phase 2 trial, with support from IDeate-PanTumor01 phase 1/2 trial Fourteenth Breakthrough Therapy Designation granted by FDA across the oncology portfolio of Daiichi Sankyo BASKING RIDGE, N.J. & RAHWAY, N.J. / Aug...Read more
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studies REDMOND, Wash. and PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that the U.S....Read more
CHICAGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today its financial results for the second quarter and six-month period ended June 30, 2025. Financial Highlights for the Three and Six Months Ended June 30, 2025 Income StatementCosmos Health continued its positive trajectory in Q2 2025, delivering...Read more
Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity1 The accelerated approval is based on Part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant improvement...Read more
Generated $1.8 million in cash flow from operations for the second quarter of 2025. Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. Increased cash position at June 30, 2025 to $18.4 million. WIXOM, Mich. / Aug 14, 2025 / Business Wire / Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of...Read more
New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty...Read more
Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3.8 Million SOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “This...Read more
Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express...Read more
First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half 2025 Adjusted EBITDA of $22.5 Million, up 35% Year-over-Year and Representing 25% Margin of Revenues; Second Quarter Adjusted EBITDA of $10.9 Million, up 20% Year-over-Year Robust First Half Results and Positive Outlook for Remainder of 2025 Support Increased Adjusted EBITDA...Read more
BEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new...Read more
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments. SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is...Read more
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium)...Read more
Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of new BX004 Phase 1b/2a data demonstrated further ~500-fold (2.7 log₁₀)2 bacterial reduction versus placebo with no detectable emergence of resistance observed, highlighting strength of BiomX platform capabilitiesPhase 2b...Read more
ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc....Read more
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect strategic focus Group revenues of € 371.2 m (-5%); D&PD (-11%) continues to see soft demand;Just - Evotec Biologics ("JEB"; +16%) exceeding expectations driven by...Read more
Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update. Highlights from the first six months of 2025 included the following: Total revenues for the second quarter...Read more
BOULDER, CO / ACCESS Newswire / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its HOCl-based diaper rash product for...Read more
New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade Construction will begin in fall 2025 with the site expected to be fully operational in 2027 Furthers AbbVie's long-term commitment to the...Read more
First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in this cisplatin-ineligible patient population, representing significant advancement in MIBC RAHWAY, N.J. / Aug 12, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline...Read more
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be discussed with global health authorities for potential regulatory filings NEW YORK & TOKYO / Aug 12, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki...Read more
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today announced that it has entered into an...Read more
Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...Read more
| Company | Change | Last Trade |
|---|---|---|
| Biogen | 7.41 5.60 | $139.63 |
| PTC Therapeutics | 3.10 6.28 | $52.43 |
| Ipsen | 2.40 7.41 | $34.78 |
| Eli Lilly | 2.02 0.28 | $734.60 |
| AbbVie | 1.52 0.72 | $211.92 |
| Merck | 1.36 1.62 | $85.48 |
| Johnson & Johnson | 0.89 0.50 | $178.06 |
| Scilex | 0.80 4.48 | $18.64 |
| Kiniksa Pharmaceuticals | 0.79 2.36 | $34.28 |
| ANI Pharmaceuticals | 0.60 0.64 | $94.10 |
| Pacira BioSciences | 0.55 2.06 | $27.22 |
| Teva Pharmaceutical | 0.37 2.01 | $18.75 |
| Collegium Pharmaceutical | 0.36 0.93 | $39.16 |
| Indivior | 0.32 1.32 | $24.60 |
| HUTCHMED | 0.31 2.07 | $15.32 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE